FY2022 EPS Estimates for Masimo Co. (NASDAQ:MASI) Cut by Jefferies Financial Group

Masimo Co. (NASDAQ:MASIGet Rating) – Jefferies Financial Group lowered their FY2022 earnings estimates for Masimo in a report issued on Wednesday, November 9th. Jefferies Financial Group analyst M. Taylor now forecasts that the medical equipment provider will post earnings of $4.48 per share for the year, down from their previous estimate of $4.52. Jefferies Financial Group currently has a “Buy” rating and a $180.00 target price on the stock. The consensus estimate for Masimo’s current full-year earnings is $4.47 per share. Jefferies Financial Group also issued estimates for Masimo’s Q4 2022 earnings at $1.21 EPS.

Masimo (NASDAQ:MASIGet Rating) last released its earnings results on Tuesday, August 9th. The medical equipment provider reported $1.35 EPS for the quarter, topping the consensus estimate of $1.19 by $0.16. Masimo had a net margin of 12.68% and a return on equity of 17.39%. The firm had revenue of $565.30 million for the quarter, compared to the consensus estimate of $540.56 million. During the same quarter in the previous year, the firm earned $0.94 earnings per share. The company’s quarterly revenue was up 87.9% compared to the same quarter last year.

A number of other research firms also recently issued reports on MASI. Loop Capital began coverage on shares of Masimo in a research note on Tuesday, September 13th. They set a “buy” rating and a $206.00 price target on the stock. StockNews.com began coverage on shares of Masimo in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Needham & Company LLC upped their price target on shares of Masimo from $163.00 to $179.00 and gave the company a “buy” rating in a research note on Wednesday, August 10th. Wolfe Research raised shares of Masimo from a “peer perform” rating to an “outperform” rating and set a $165.00 price target on the stock in a research note on Thursday, September 15th. Finally, Stifel Nicolaus upped their price target on shares of Masimo from $162.00 to $172.00 and gave the company a “buy” rating in a research note on Monday, September 12th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $190.29.

Masimo Price Performance

MASI stock opened at $121.58 on Thursday. Masimo has a one year low of $108.89 and a one year high of $305.21. The company’s fifty day moving average price is $138.99 and its 200-day moving average price is $138.57. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.28 and a current ratio of 2.10. The company has a market capitalization of $6.39 billion, a PE ratio of 40.26 and a beta of 0.87.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Masimo by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock valued at $695,050,000 after acquiring an additional 71,918 shares during the last quarter. FMR LLC increased its position in Masimo by 1.7% during the second quarter. FMR LLC now owns 2,104,939 shares of the medical equipment provider’s stock valued at $275,052,000 after acquiring an additional 35,438 shares during the last quarter. Nomura Holdings Inc. bought a new position in Masimo during the second quarter valued at $242,537,000. State Street Corp increased its position in Masimo by 1.6% during the first quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock valued at $251,928,000 after acquiring an additional 27,261 shares during the last quarter. Finally, Liontrust Investment Partners LLP grew its holdings in shares of Masimo by 19.0% in the second quarter. Liontrust Investment Partners LLP now owns 1,199,300 shares of the medical equipment provider’s stock worth $156,713,000 after purchasing an additional 191,700 shares during the last quarter. Institutional investors own 93.31% of the company’s stock.

About Masimo

(Get Rating)

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Read More

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.